Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21504261 | 0.87 | IDO1 (0.48) | IDO1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21504008 | 0.82 | IDO1 (0.53) | IDO1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30056917 | 0.80 | IDO1 (0.69) | IDO1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26783436 | 0.77 | IDO1 (0.44) | IDO1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21504197 | 0.76 | IDO1 (0.50) | IDO1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21504150 | 0.76 | IDO1 (0.65) | IDO1SMN1; SMN2MAPT | |
| SCHEMBL4740817 | 0.73 | KCNQ3 (0.68) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL26783502 | 0.73 | IDO1 (0.44) | IDO1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL26783412 | 0.72 | IDO1 (0.42) | IDO1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21504253 | 0.72 | IDO1 (0.55) | IDO1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | IDO1 1/4885ALDH1A1 144/4885NPC1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.